Drug Trial Radar · NCT06343714
A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects
Last checked: Nov 20, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Apr 7, 2024
Primary completion
Feb 28, 2026
Study completion May 30, 2026
Sponsor
- Lead sponsor
- 4B Technologies LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of Part 1 is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening. The purpose of Part 2 is to assess the safety, tolerability, PK and efficacy of SAD of SC administered FB1003 in adult subjects with osteoarthritis (OA) pain.
Conditions
- Healthy Volunteers
Interventions
FB1003Drug
Subcutaneous (SC) injection
PlaceboDrug
Subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo.Time frame: Baseline to end of study, SAD up to 56 days and MAD up to 84 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Queensland, Australia · Completed
Veritus Research
Bayswater, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.